How is the U.S. going to end its opioid crisis?
The answer really shouldn't be that difficult. The president goes on TV to declare a national emergency. He increases the budget of the Substance Abuse and Mental Health Services Administration by several billion dollars, with the money earmarked for curbing opioid addiction. The Department of Health and Human Services cracks down on excessive opioid distribution, while the Justice Department goes after opioid manufacturers like Purdue Pharma Inc., distributors like McKesson Corp. and egregious overprescribing doctors. At the same time, the government underwrites therapies that block opioid cravings and takes other steps to help addicts break the habit. As the number of opioid-related deaths declines, the president takes a victory lap as his re-election nears.
Inexplicably, President Donald Trump seems uninterested in taking these obvious steps. Yes, he created an opioid commission, whose recommendations he has ignored, and declared a "national health emergency." But instead of adding funding, he actually proposed cutting the substance abuse budget by $400 million. And of course nothing signaled Trump's lack of seriousness than the person he named to be his "opioid czar": Kellyanne Conway, the spinmeister best known for rebranding Trump's fantasies as "alternative facts."
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.